Hina J Shah
Overview
Explore the profile of Hina J Shah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kavanaugh M, Shah H
Clin Nucl Med
. 2024 Mar;
49(5):457-458.
PMID: 38465978
A 75-year-old woman with history of metastatic lung adenocarcinoma in remission develops new widespread FDG-avid lymphadenopathy in the neck, chest, abdomen, and pelvis on surveillance PET/CT, as well as intense...
2.
Singh A, Shah H, Dabiri B, Landman W
Clin Nucl Med
. 2024 Feb;
49(5):e202-e205.
PMID: 38389212
A 68-year-old woman presented with chest pain and shortness of breath. Imaging revealed a left hilar mass biopsy-proven as small cell cancer. Concurrently, a macroscopic fat-containing renal lesion consistent with...
3.
Kavanaugh M, Shah H
J Nucl Cardiol
. 2024 Jan;
35:101814.
PMID: 38246258
Vicarious excretion of tracer and contrast media is a known phenomenon and is not fully understood [1,2]. We report a case of unexpected vicarious excretion of Tc-pyrophosphate in the gallbladder...
4.
Shah H, Ruppell E, Bokhari R, Aland P, Lele V, Ge C, et al.
Eur J Radiol Open
. 2023 Feb;
10:100477.
PMID: 36785643
As new molecular tracers are identified to target specific receptors, tissue, and tumor types, opportunities arise for the development of both diagnostic tracers and their therapeutic counterparts, termed "theranostics." While...
5.
Spinali K, Papke D, Shah H
Clin Nucl Med
. 2023 Feb;
48(4):e181-e183.
PMID: 36728165
18 F-DCFPyl is a Food and Drug Administration-approved radiotracer that targets prostate-specific membrane antigen and is used in the detection of recurrent or metastatic prostate cancer. As its use has...
6.
Wrenn S, Moore A, Shah H, Barletta J, Vaidya A, Kilbridge K, et al.
Am J Surg
. 2022 Sep;
225(2):309-314.
PMID: 36137821
Background: Adrenocortical carcinoma (ACC) is an aggressive, rare malignancy. 2-deoxy-2-[18F]-fluoro-d-glucose positron emission tomography (FDG-PET) assesses tumor metabolism and glucose utilization. We hypothesized that higher maximum standard uptake value (SUV) is...
7.
Shah H, Halpern J, Watane G, Hyun H
Clin Nucl Med
. 2021 May;
47(1):e56-e58.
PMID: 34028403
COVID vaccination has begun in most of the countries. Older population and high-risk groups are prioritized for vaccination. Postvaccination imaging in cancer patients may show effects of the immune response...
8.
Schoenfeld J, Hanna G, Jo V, Rawal B, Chen Y, Catalano P, et al.
JAMA Oncol
. 2020 Aug;
6(10):1563-1570.
PMID: 32852531
Importance: Novel approaches are needed to improve outcomes in patients with squamous cell carcinoma of the oral cavity. Neoadjuvant immunotherapy given prior to surgery and combining programmed cell death protein...
9.
Alessandrino F, Shah H, Ramaiya N
Clin Imaging
. 2018 Jan;
50:96-103.
PMID: 29348053
Immune-related endocrine adverse events occur in up to one third of patients treated with immune checkpoint inhibitors. The purpose of this article is to provide a comprehensive review of the...
10.
Shah H, Keraliya A, Jagannathan J, Tirumani S, Lele V, DiPiro P
Korean J Radiol
. 2017 Jan;
18(1):54-70.
PMID: 28096718
Diffuse large B cell lymphoma (DLBCL) is the most common histological subtype of Non-Hodgkin's lymphoma. As treatments continues to evolve, so do imaging strategies, and positron emission tomography (PET) has...